Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. Masimo is committed to improving patient outcomes and reducing cost of care by working with dedicated hospital staff to convert healthcare institutions around the world to Masimo SET pulse oximetry technology. We are accomplishing this goal through partnering with our patient monitoring companies and caregivers and creating innovative, cost-effective acquisition programs for Masimo SET products for the benefit of the patients. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the company’s growth opportunities. For more than 20 years now, Masimo has been focused on a singular mission — to create noninvasive patient monitoring technologies that are more effective and reliable and to improve patient outcomes and reduce the cost of care by bringing these technologies to new sites and applications. The result is a portfolio of clinically-proven products that lead the way in innovation, performance and patient safety by giving health care providers the information they need to optimize clinical decision-making.
Closing share price
|FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$547.2 m||$586.6 m||$630.1 m||$694.6 m|
Revenue growth, %
|$55.7 m||$74.4 m||$81.5 m||$300.7 m|